Changes in the Composition of the Human Fecal Microbiome After Bacteriotherapy for Recurrent Clostridium difficile-associated Diarrhea
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
CDAD is the major known cause of antibiotic-induced diarrhea and colitis, and the disease is thought to result from persistent disruption of commensal gut microbiota.Bacteriotherapy by way of fecal transplantation can be used to treat recurrent CDAD and is thought to re-establish the normal colonic microflora.However, limitations of conventional microbiologic techniques have until recently precluded testing of this idea.In this study we used T-RFLP and 16S rRNA gene sequencing approaches to characterize the bacterial composition of the colonic microflora in a patient suffering from recurrent CDAD, before and after treatment by fecal transplantation from a healthy donor.While the patient's residual colonic microbiota, prior to therapy, was deficient in members of the bacterial divisions-Firmicutes and Bacteriodetes, transplantation had a dramatic impact on the composition of the patient's gut microbiota.By 14 days post transplantation, the fecal bacterial composition of the recipient was highly similar to the donor and was dominated by Bacteroides spp.strains and an uncharacterized butyrate producing bacterium.The change in bacterial composition was accompanied by resolution of the patient's symptoms.The striking similarity of the recipient's and donor's intestinal microbiota following bacteriotherapy suggests that the donor's bacteria quickly occupied their requisite niches, resulting in restoration of both the structure and function of the microbial communities present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated remarkable effectiveness of FMT in cases of recurrent and refractory CDI, which may be attributed to sustained restoration of the normal microbiota after FMT.22,23”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
In the citing paper
“Moreover, the restoration of more typical microbial communities, which come to resemble those of the donor post-transplant, persists in a durable fashion after FMT.6, 7”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
In the citing paper
“FMT appears to result in durable engraftment of new species from donor as well as augmentation of species present at only very low levels prior to FMT6.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Muyzer, G., de Waal, E. C., & Uitterlinden, A. G. (1993) · Applied and Environmental Microbiology · doi:10.1128/aem.59.3.695-700.1993 · Cited by 11,429
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 1×
“Many Firmicutes produce butyrate and are postulated to be involved in obesity in humans and murine models.(32,33) Short chain length fatty acids (SCFAs), especially butyrate, have also been shown to play a critical role in maintaining integrity of the colonic epithelium and regulation of the mucosal immune responses.”
BackgroundDiversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006) · Cell · doi:10.1016/j.cell.2006.02.017 · Cited by 3,358 · cited 1×
“These bacteria are well-known dominant members of human fecal microbiota,(16) and these phyla are thought to play major ecologic roles in establishment and maintenance of gut homeostasis.(30) A lack of Bacteroides sp.”
BackgroundDevelopment of the Human Infant Intestinal Microbiota
Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A., & Brown, P. O. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050177 · Cited by 2,877
Edwards, U., Rogall, T., Blöcker, H., Emde, M., & Böttger, E. C. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.19.7843 · Cited by 2,724 · cited 1×
“primers Bact-8F (5’-AGAGTTTGATCCTGGCTCAG-3’) [25] 5′ end-labeled with 6-”
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 4×
“Unfortunately, the same problem is encountered by others treating this disease.(1) In the studies reported here, we used a molecular approach to gain a better understanding of the bacterial composition of the GI tract in a CDAD patient.”
BackgroundInfluentialDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 2×
“However, the composition and species richness of intestinal tract microbiota in individuals with CDAD and recurrent CDAD were found to be markedly different from controls.(14) The reestablishment of the normal composition of the intestinal flora has long been hypothesized to be a curative approach for the recurrent CD…”
Background
Cited by
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
“Other important clinical applications of metagenomic analyses include probiotic treatments [94,95] and microbiome transplantation [96-99] for gastrointestinal diseases.”
BackgroundDiversity, stability and resilience of the human gut microbiota
Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012) · Nature · doi:10.1038/nature11550 · Cited by 5,533
Self-citationThe impact of the gut microbiota on human health: an integrative view
Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012) · Cell · doi:10.1016/j.cell.2012.01.035 · Cited by 3,710
“Khoruts et al. showed how transplanting the microbial community from a healthy donor to a patient suffering from Clostridium difficileassociated disease (CDAD) significantly modified the bacterial composition in the patient (Khoruts et al., 2010).”
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Human Genetics Shape the Gut Microbiome
Goodrich, J. K., Waters, J. L., Poole, A. C., Sutter, J. L., Koren, O., Blekhman, R., Beaumont, M., Van Treuren, W., Knight, R., Bell, J. T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.053 · Cited by 3,164
“Because the microbiome can be modified for therapeutic applications (Borody and Khoruts, 2012; Hamilton et al., 2013; Khoruts et al., 2010; van Nood et al., 2013), it constitutes an attractive target for manipulation.”
The role of the gut microbiota in nutrition and health
Flint, H. J., Scott, K. P., Louis, P., & Duncan, S. H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.156 · Cited by 2,182
How glycan metabolism shapes the human gut microbiota
Koropatkin, N. M., Cameron, E. A., & Martens, E. C. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2746 · Cited by 1,419
Diet, gut microbiota and immune responses
Maslowski, K. M., & Mackay, C. R. (2011) · Nature Immunology · doi:10.1038/ni0111-5 · Cited by 1,261
Ursell, L. K., Metcalf, J. L., Parfrey, L. W., & Knight, R. (2012) · Nutrition Reviews · doi:10.1111/j.1753-4887.2012.00493.x · Cited by 1,255
“difficile infection is replaced by the donor community[67, 73].”
BackgroundThe microbiome in early life: Implications for health outcomes
Tamburini, S., Shen, N., Wu, H. C., & Clemente, J. C. (2016) · Nature Medicine · doi:10.1038/nm.4142 · Cited by 1,213
Current Understanding of Dysbiosis in Disease in Human and Animal Models
DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000750 · Cited by 1,122
“Post-FMT results in the expansion and restoration of bacteria derived from the donor in the patient within 2 weeks to 1 month.(96) Currently, FMT is being considered for other diseases such as insulin resistance, and IBD.”
BackgroundGough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003
“Various reports have documented changes to the intestinal microbiota after IMT [44, 48, 61], and the microbiota of treated patients typically has been shown to resemble that of the donor after infusion [44, 61].”
BackgroundTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Self-citationKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Bäckhed, F., Fraser, C. M., Ringel, Y., Sanders, M. E., Sartor, R. B., Sherman, P. M., Versalovic, J., Young, V., & Finlay, B. B. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.10.012 · Cited by 836
Greenblum, S., Turnbaugh, P. J., & Borenstein, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116053109 · Cited by 821
Socially transmitted gut microbiota protect bumble bees against an intestinal parasite
Koch, H., & Schmid-Hempel, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110474108 · Cited by 824
Factors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
“Regardless of the route of FMT, there is enough evidence supporting the conclusion that FMT is a highly efficient, and therapeutic option for several intestinal diseases, characterized by ability to restore the compositions and functions of gut microbiota which are similar to gut microbiota of recipients (Khoruts et a…”
BackgroundThe Gastrointestinal Microbiome: A Review
Barko, P. C., McMichael, M. A., Swanson, K. S., & Williams, D. A. (2018) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14875 · Cited by 750
Shifting the balance: antibiotic effects on host–microbiota mutualism
Willing, B. P., Russell, S. L., & Finlay, B. B. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2536 · Cited by 747
“New therapeutic approaches towards this aim include faecal bacteriotherapy from healthy donors following antibiotic treatment, and exogenous immune activation during the course of antibiotic therap”
BackgroundHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738
Self-citationPetrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731
“Our study showed that the microbiota of both patients adapted characteristics of the stool substitute mixture yet still retained some of their original microbiota, similar to that described for stool transplants [20].”
BackgroundResultSequencing and beyond: integrating molecular 'omics' for microbial community profiling
Franzosa, E. A., Hsu, T., Sirota-Madi, A., Shafquat, A., Abu-Ali, G., Morgan, X. C., & Huttenhower, C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3451 · Cited by 719
Therapeutic Potential of Fecal Microbiota Transplantation
Smits, L. P., Bouter, K. E. C., de Vos, W. M., Borody, T. J., & Nieuwdorp, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.058 · Cited by 717
Experimental and analytical tools for studying the human microbiome
Kuczynski, J., Lauber, C. L., Walters, W. A., Parfrey, L. W., Clemente, J. C., Gevers, D., & Knight, R. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3129 · Cited by 709
“Causality has been established in a few cases: stool transplantations from one human to another can cure persistent Clostridium difficile infection”
BackgroundGut microbiome-host interactions in health and disease
Kinross, J. M., Darzi, A. W., & Nicholson, J. K. (2011) · Genome Medicine · doi:10.1186/gm228 · Cited by 691
“Several studies now suggest that fecal transplantation may be beneficial in states of antibiotic-associated diarrhea or Clostridium difficile infection [86-88].”
BackgroundFecal microbiota transplantation and emerging applications
Borody, T. J., & Khoruts, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.244 · Cited by 677
“The prompt reconstitution of normal microbiota in FMT, even with a single infusion, is therefore so complete and durabl”
BackgroundSelf-citationBrandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Microbiota restoration: natural and supplemented recovery of human microbial communities
Reid, G., Younes, J. A., Van der Mei, H. C., Gloor, G. B., Knight, R., & Busscher, H. J. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2473 · Cited by 588
Interaction of gut microbiota with bile acid metabolism and its influence on disease states
Staley, C., Weingarden, A. R., Khoruts, A., & Sadowsky, M. J. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-8006-6 · Cited by 581
“Notably, germination of spores from the strain of Cl. difficile isolated from this patient was found to be inhibited by UDCA, again supporting the idea that bile acid supplements may represent an alternative treatment for CDI in select patients.”
BackgroundInfluentialSelf-citationUpdate on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Understanding the mechanisms of faecal microbiota transplantation
Khoruts, A., & Sadowsky, M. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.98 · Cited by 561
Self-citationHuman Microbiome in Health and Disease
Pflughoeft, K. J., & Versalovic, J. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132421 · Cited by 529
Cesarean Versus Vaginal Delivery: Long-term Infant Outcomes and the Hygiene Hypothesis
Neu, J., & Rushing, J. (2011) · Clinics in Perinatology · doi:10.1016/j.clp.2011.03.008 · Cited by 529
“Excitement about the potential of harnessing the intestinal microbiota for therapeutic purposes and health is reflected by the popularity of probiotics and prebiotics and by even such seemingly esoteric therapies as human fecal transplant.(15) Not all the microbial species in the gut have been identified because most…”
BackgroundCan probiotics modulate human disease by impacting intestinal barrier function?
Bron, P. A., Kleerebezem, M., Brummer, R.-J., Cani, P. D., Mercenier, A., MacDonald, T. T., Garcia-Ródenas, C. L., & Wells, J. M. (2017) · British Journal Of Nutrition · doi:10.1017/s0007114516004037 · Cited by 499
“difficile-associated disease, which has been successful even after the failure of multiple courses of antibiotics((220,221)).”
BackgroundChapter 12: Human Microbiome Analysis
Morgan, X. C., & Huttenhower, C. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002808 · Cited by 496
“Within days, not only had she begun a complete recovery, but a metagenomic survey of her microbiota showed that the new community was almost completely established and had restored normal taxonomic abundances [162].”
BackgroundAntharam, V. C., Li, E. C., Ishmael, A., Sharma, A., Mai, V., Rand, K. H., & Wang, G. P. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00845-13 · Cited by 485
“Following FMT, the gut microbiota of the recipient resembles that of the donor (12).”
BackgroundFecal microbiota transplantation: in perspective
Gupta, S., Allen-Vercoe, E., & Petrof, E. O. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15607414 · Cited by 481
Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease
Weingarden, A. R., & Vaughn, B. P. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1290757 · Cited by 463
Strategies to Minimize Antibiotic Resistance
Lee, C.-R., Cho, I., Jeong, B., & Lee, S. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10094274 · Cited by 446
“To minimize these effects, some strategies such as bacteriotherapy [73], probiotic intervention [91],”
BackgroundAsnicar, F., Manara, S., Zolfo, M., Truong, D. T., Scholz, M., Armanini, F., Ferretti, P., Gorfer, V., Pedrotti, A., Tett, A., et al. (2017) · mSystems · doi:10.1128/msystems.00164-16 · Cited by 445
“The essential role of the intestinal microbiome is probably best exemplified by the successful treatment of dysbiotic states such as chronic life threatening Clostridium difficile infections using microbiome transplantation therapies (7-9).”
BackgroundRole of the intestinal microbiome in health and disease: from correlation to causation
de Vos, W. M., & de Vos, E. A. (2012) · Nutrition Reviews · doi:10.1111/j.1753-4887.2012.00505.x · Cited by 440
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
“Rubin et al31 USA 74 63 (6-94) Recurrent (2 or more) Stomach/ nasogastric tube 64) Percutaneous gastrostomy tube (4) Upper endoscopy (7) 30/50-70 59/57 12wk O: M-V”
BackgroundInfluentialCosta, M. C., Arroyo, L. G., Allen-Vercoe, E., Stämpfli, H. R., Kim, P. T., Sturgeon, A., & Weese, J. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041484 · Cited by 425
“difficile infection (CDI) in humans [24,40].”
BackgroundMeta-analyses of studies of the human microbiota
Lozupone, C. A., Stombaugh, J., Gonzalez, A., Ackermann, G., Wendel, D., Vázquez-Baeza, Y., Jansson, J. K., Gordon, J. I., & Knight, R. (2013) · Genome Research · doi:10.1101/gr.151803.112 · Cited by 424
“…(Wang et al. 2011), disturbances produced by antibiotics (Jakobsson et al. 2010; Dethlefsen and Relman 2011) including Clostridium difficile colitis (Chang et al. 2008; Khoruts et al. 2010; Gough et al. 2011), and other forms of inflammatory bowel diseases (Willing et al. 2010).”
BackgroundSelf-citationWeingarden, A. R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V. M., Sadowsky, M. J., & Khoruts, A. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2013 · Cited by 423
“Previous work by our group and others has demonstrated dramatic changes in the fecal microbiota of patients undergoing FMT, with fecal microbial communities becoming more similar to that of the donor, including an increased abundance of Bacteroidetes and Firmicutes, a decreased abundance of Proteobacteria, and an incr…”
ResultSelf-citationThe microbiome as a human organ
Baquero, F., & Nombela, C. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03916.x · Cited by 415
“shown to be highly similar to the donor [17].”
BackgroundSystematic Review: Adverse Events of Fecal Microbiota Transplantation
Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., & Wang, B. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161174 · Cited by 409
“Gustafsson, 1998 [71] Diarrhea Lee CH, 2014 [72] Transient constipation; Excess flatulence Hamilton, 2012 [73] Irregularity of bowel movements; Excessive flatulence Khoruts, 2010 [74] Constipation; Irregularity of bowel movements Kelly, 2014 [84] Death from aspiration; Minor mucosal tear Fever; Bloating; Abdominal dis…”
Santoru, M. L., Piras, C., Murgia, A., Palmas, V., Camboni, T., Liggi, S., Ibba, I., Lai, M. A., Orrù, S., Blois, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10034-5 · Cited by 387
Ferreyra, J. A., Wu, K. J., Hryckowian, A. J., Bouley, D. M., Weimer, B. C., & Sonnenburg, J. L. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.11.003 · Cited by 378
“Fecal transplants have been found to be effective in curing recurrent CDAD, consistent with the importance of a healthy gut ecosystem in outcompeting C. difficile (Khoruts et al. 2010; van Nood et al. 2013).”
BackgroundRea, M. C., Dobson, A., O'Sullivan, O., Crispie, F., Fouhy, F., Cotter, P. D., Shanahan, F., Kiely, B., Hill, C., & Ross, R. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001224107 · Cited by 377
“With respect to CDAD and antibiotic treatment, the strategies that have been used to address this issue include supplementation of the diet with probiotics (26, 32) and fecal transplantation (33).”
MethodAntibiotic treatment for Clostridium difficile -associated diarrhoea in adults
Nelson, R. L., Suda, K. J., & Evans, C. T. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004610.pub5 · Cited by 366
Zuo, T., Wong, S. H., Lam, K., Lui, R., Cheung, K., Tang, W., Ching, J. Y. L., Chan, P. K. S., Chan, M. C. W., Wu, J. C. Y., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-313952 · Cited by 346
Probiotics for Prevention and Treatment of Diarrhea
Guandalini, S. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182257e98 · Cited by 346
Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota
Xu, J., Chen, H., & Li, S. (2017) · Medicinal Research Reviews · doi:10.1002/med.21431 · Cited by 340
Halkjær, S. I., Christensen, A. H., Lo, B. Z. S., Browne, P. D., Günther, S., Hansen, L. H., & Petersen, A. M. (2018) · Gut · doi:10.1136/gutjnl-2018-316434 · Cited by 338
Fecal microbiota transplantation: past, present and future
Aroniadis, O. C., & Brandt, L. J. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a4b3e · Cited by 336
Reshaping the gut microbiome with bacterial transplantation and antibiotic intake
Manichanh, C., Reeder, J., Gibert, P., Varela, E., Llopis, M., Antolin, M., Guigo, R., Knight, R., & Guarner, F. (2010) · Genome Research · doi:10.1101/gr.107987.110 · Cited by 335
“Attempts to manipulate the composition of the intestinal microbiome by fecal bacteriotherapy have now become the focus of an extensive body of clinical case reports with promising results (Borody et al. 2003; You et al. 2008; Khoruts et al. 2009; Shanahan 2009).”
BackgroundConnecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex
Rizzetto, L., Fava, F., Tuohy, K. M., & Selmi, C. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.008 · Cited by 331
Recovery of the Gut Microbiome following Fecal Microbiota Transplantation
Seekatz, A. M., Aas, J., Gessert, C. E., Rubin, T. A., Saman, D. M., Bakken, J. S., & Young, V. B. (2014) · mBio · doi:10.1128/mbio.00893-14 · Cited by 331
“antibiotic use (7), it is still unknown whether a specific microbial”
BackgroundAngelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.257 · Cited by 330
Antimicrobial peptides and gut microbiota in homeostasis and pathology
Ostaff, M. J., Stange, E. F., & Wehkamp, J. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201773 · Cited by 329
“Shifts from a disease related dysbiosis towards a healthier state in recipients have been reported but these often relate to quite small collectives, which are limited to C. dif fi cile infected patients (Grehan et al, 2010; Khoruts et al, 2010).”
McHardy, I. H., Goudarzi, M., Tong, M., Ruegger, P. M., Schwager, E., Weger, J. R., Graeber, T. G., Sonnenburg, J. L., Horvath, S., Huttenhower, C., et al. (2013) · Microbiome · doi:10.1186/2049-2618-1-17 · Cited by 322
“In twin-pair studies, Crohn’s disease-associated differences in fecal metabolites have been detected in parallel with microbial compositional and metagenomic differences in this compartment, and represented biomarkers related to disease state, presumably in part as products of the disease-associated changes in microbi…”
BackgroundFecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives
Choi, H. H., & Cho, Y.-S. (2016) · Clinical Endoscopy · doi:10.5946/ce.2015.117 · Cited by 318
“Khoruts et al.(14) used molecular approaches to characterize the bacterial composition of the colonic microbiota before and after FMT in a patient with CDI.”
Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A., & Sadowsky, M. J. (2013) · Gut Microbes · doi:10.4161/gmic.23571 · Cited by 315
“Our results suggest that engraftment of a standardized and frozen preparation of donor fecal microbiota restores the protective effect provided by the normal flora similar to that seen when using fresh donor material from a familial donor.(15) While additional experiments are required to determine the key taxa involve…”
BackgroundResultInfluentialSelf-citationKunde, S., Pham, A., Bonczyk, S., Crumb, T., Duba, M., Conrad, H., Cloney, D., & Kugathasan, S. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318292fa0d · Cited by 314
“Recent evidence suggests that FMT, the infusion of fecal preparation from a healthy donor into the GI tract of a patient, is capable of altering the gut microbiome of the new host (6,7).”
BackgroundMethodSynthetic microbial ecosystems: an exciting tool to understand and apply microbial communities
De Roy, K., Marzorati, M., Van den Abbeele, P., Van de Wiele, T., & Boon, N. (2014) · Environmental Microbiology · doi:10.1111/1462-2920.12343 · Cited by 313
Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease
Anderson, J. L., Edney, R. J., & Whelan, K. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05220.x · Cited by 313
The intestinal microbiota and chronic disorders of the gut
DuPont, A. W., & DuPont, H. L. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.133 · Cited by 307
A Critical Review on Health Promoting Benefits of Edible Mushrooms through Gut Microbiota
Jayachandran, M., Xiao, J., & Xu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091934 · Cited by 294
“Treatment for two weeks significantly prevented the dysbiosis and the symptoms associated with CDAD were found to have disappeared [61].”
BackgroundFecal microbiota transplantation
Vindigni, S. M., & Surawicz, C. M. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.012 · Cited by 283
Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions
Borody, T. J., Paramsothy, S., & Agrawal, G. (2013) · Current Gastroenterology Reports · doi:10.1007/s11894-013-0337-1 · Cited by 275
Banerjee, S., Sindberg, G., Wang, F., Meng, J., Sharma, U., Zhang, L., Dauer, P., Chen, C., Dalluge, J., Johnson, T., et al. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.9 · Cited by 266
Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives
Salonen, A., de Vos, W. M., & Palva, A. (2010) · Microbiology · doi:10.1099/mic.0.043257-0 · Cited by 264
“, 2007), and from an individual suffering from Clostridium difficile-associated disease (CDAD) with severe diarrhoea and colitis (Khoruts et al., 2010).”
BackgroundAn overview of fecal microbiota transplantation: techniques, indications, and outcomes
Brandt, L. J., & Aroniadis, O. C. (2013) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.03.1329 · Cited by 258
Clostridium difficile and the microbiota
Seekatz, A. M., & Young, V. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72336 · Cited by 255
“Earlier studies using either culture-based or PCR-based methods have reported the recovery of Bacteroides species and detection of more Firmicutes in culture, only after the FMT procedure, along with successful clinical recovery (74, 75).”
MethodEnvironment shapes the fecal microbiome of invasive carp species
Eichmiller, J. J., Hamilton, M. J., Staley, C., Sadowsky, M. J., & Sorensen, P. W. (2016) · Microbiome · doi:10.1186/s40168-016-0190-1 · Cited by 254
“Manipulation of gut microbiota to influence health has recently received greater attention in humans through procedures such as fecal microbiota transplantation [18, 19].”
BackgroundSelf-citationWeingarden, A., González, A., Vázquez-Baeza, Y., Weiss, S., Humphry, G., Berg-Lyons, D., Knights, D., Unno, T., Bobr, A., Kang, J., et al. (2015) · Microbiome · doi:10.1186/s40168-015-0070-0 · Cited by 248
“As shown previously [2-8], the relative abundance of bacterial phyla in patient fecal samples shifted substantially following FMT, with relative decreases in Proteobacteria and relative increases in Bacteroidetes and Firmicutes (Figure 3).”
BackgroundSelf-citationBritton, R. A., & Young, V. B. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.04.001 · Cited by 240
“Additionally, fecal transplantation was demonstrated to have a profound effect on the fecal microbiota of recipients [31].”
BackgroundFecal microbiota transplantation broadening its application beyond intestinal disorders
Xu, M.-Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.102 · Cited by 231
Damman, C. J., Miller, S. I., Surawicz, C. M., & Zisman, T. L. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.93 · Cited by 226
Beneficial modulation of the gut microbiota
Walsh, C. J., Guinane, C. M., O'Toole, P. W., & Cotter, P. D. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.035 · Cited by 274
“nent of a CDI patient’s microbiota before and after FMT intervention [137] and found that, before intervention, the micro-”
BackgroundRecurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention
Song, J. H., & Kim, Y. S. (2019) · Gut and Liver · doi:10.5009/gnl18071 · Cited by 219
“FMT restores these changes in bacterial composition and improves rCDI symptoms.(48) Studies have shown that FMT produced a primary cure rate of approximately 90% in patients with rCDI.”
BackgroundProbiotics for Prevention and Treatment of Diarrhea
Guarino, A., Guandalini, S., & Lo Vecchio, A. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000349 · Cited by 217
De Leon, L. M., Watson, J. B., & Kelly, C. R. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.045 · Cited by 215
Fecal microbiota transplantation in relapsing Clostridium difficile infection
Rohlke, F., & Stollman, N. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12453637 · Cited by 211
“However, current literature is suggesting increasingly that for patients with infections that fail to resolve with traditional antibiotic regimens, FMT’s average cure rate of > 90% [Borody et al. 2001; Bowden et al. 1981; Garborg et al. 2010; Girotra et al. 2011; Gough et al. 2011; Hellemans et al. 2009; Khoruts et al…”
BackgroundMethodInfluentialThe intestinal microbiota and its role in human health and disease
Kataoka, K. (2016) · The Journal of Medical Investigation · doi:10.2152/jmi.63.27 · Cited by 211
Inflammation in acute and chronic pancreatitis
Habtezion, A. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000195 · Cited by 209
Preserving microbial diversity
Bello, M. G. D., Knight, R., Gilbert, J. A., & Blaser, M. J. (2018) · Science · doi:10.1126/science.aau8816 · Cited by 205
McLoughlin, R. M., & Mills, K. H. G. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.02.012 · Cited by 201
“This change in bacterial composition was accompanied by resolution of the disease.(92) An alternative therapeutic strategy might be to harness the immunomodulatory properties of specific bacterial components and administer these molecules to adjust the immune imbalances occurring in allergic subjects.”
BackgroundTherapeutic modulation of intestinal dysbiosis
Walker, A. W., & Lawley, T. D. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.09.008 · Cited by 200
Emerging trends and research foci in gastrointestinal microbiome
Huang, X., Fan, X., Ying, J., & Chen, S. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1810-x · Cited by 197
“010910 Gut microbiome can be reprogrammed to restore beneficial host structure and functions [22]”
BackgroundShahinas, D., Silverman, M., Sittler, T., Chiu, C., Kim, P., Allen-Vercoe, E., Weese, S., Wong, A., Low, D. E., & Pillai, D. R. (2012) · mBio · doi:10.1128/mbio.00338-12 · Cited by 191
“It has been suggested that the CDI state is marked by reduced microbial diversity and that persistent disruption of commensal microbe-gut interactions may result in interference with the complex interactions between the host and the commensal gut microbiota of healthy individuals (11, 12, 18).”
BackgroundMethodAgrawal, M., Aroniadis, O. C., Brandt, L. J., Kelly, C., Freeman, S., Surawicz, C., Broussard, E., Stollman, N., Giovanelli, A., Smith, B., et al. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000410 · Cited by 186
Kelly, C. R., de Leon, L., & Jasutkar, N. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318234570b · Cited by 190
“flora.(15) Numerous case reports and retrospective case series have demonstrated benefit of FMT in patients with severe or recurrent CDI with cure rates as high as 100% and a mean cure rate of 96% for the approximately 200 cases reported in the world literature.”
BackgroundFrom Stool Transplants to Next-Generation Microbiota Therapeutics
Petrof, E. O., & Khoruts, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.004 · Cited by 186
Self-citationAltering Host Resistance to Infections through Microbial Transplantation
Willing, B. P., Vacharaksa, A., Croxen, M., Thanachayanont, T., & Finlay, B. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026988 · Cited by 186
“been seen in fecal transplantation to patients suffering from Clostridium difficile-associated diarrhea [28].”
BackgroundAdverse events in faecal microbiota transplant: a review of the literature
Baxter, M., & Colville, A. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.10.024 · Cited by 185
Rapidly expanding knowledge on the role of the gut microbiome in health and disease
Cénit, M. C., Matzaraki, V., Tigchelaar, E. F., & Zhernakova, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.023 · Cited by 184
“The recent success story of fecal transplantation in a patient suffering from Clostridium difficile-associated diarrhea has opened up a promising new future for treating such patients by restoring their intestinal microbial balance [143] and the potential of fecal microbiota transplantation therapy is now being explor…”
Background
Metadata
- Authors
- Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J.
- Affiliations
- University of Minnesota (US)
- Swedish University of Agricultural Sciences (SE)
- Lawrence Berkeley National Laboratory (US)
- Corresponding author
- Khoruts, Alexander
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2010-05
- Volume
- 44
- Issue
- 5
- Pages
- 354-360
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2095040140
- Cited by
- 649
- References
- 37
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 22 · 2023: 14 · 2022: 13 · 2021: 26 · 2020: 29 · 2019: 41 · 2018: 49 · 2017: 49 · 2016: 53 · 2015: 49 · 2014: 69 · 2013: 88 · 2012: 47
- FWCI
- 44.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile-associated diarrhea, fecal microbiota transplantation, gut microbiota composition, colonic microbiota, Firmicutes, Bacteroidetes, Bacteroides, butyrate-producing bacteria, antibiotic-associated diarrhea
- MeSH terms
- Enterocolitis, Pseudomembranous, Feces, Female, Follow-Up Studies, Humans, Middle Aged, Polymorphism, Restriction Fragment Length, RNA, Ribosomal, 16S, Clostridioides difficile, Sequence Analysis, RNA, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.